Table 1.
Descriptive characteristics of 271,173 patients with stage I to III breast cancer according to age at diagnosis from SEER data.
| Age at diagnosis |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| <40 years N = 14,109 |
40–60 years N = 122,188 |
60–75 years N = 96,837 |
>75 years N = 38,039 |
||||||
| No. | % | No. | % | No. | % | No. | % | p value | |
| Race/Ethnicity | |||||||||
| White/non-Hispanic | 7304 | 51.8 | 77100 | 63.1 | 70433 | 72.7 | 29739 | 78.2 | <0.001 |
| Hispanic | 2798 | 32.8 | 16536 | 13.5 | 8572 | 8.9 | 2618 | 6.9 | |
| Black/non-Hispanic | 2086 | 24.5 | 14596 | 11.9 | 9449 | 9.8 | 3165 | 8.3 | |
| Asian, PI/non-Hispanic | 1726 | 20.2 | 12564 | 10.3 | 7363 | 7.6 | 2234 | 5.9 | |
| Others/unknown | 195 | 2.3 | 1392 | 1.1 | 1020 | 1.1 | 283 | 0.7 | |
| Insurance | |||||||||
| Insured | 11169 | 79.2 | 102651 | 84.0 | 87602 | 90.5 | 35084 | 92.2 | <0.001 |
| Medicaid | 2440 | 17.3 | 16723 | 13.7 | 8312 | 8.6 | 2831 | 7.4 | |
| Uninsured/unknown | 500 | 3.5 | 2814 | 2.3 | 923 | 1.0 | 124 | 0.3 | |
| SEER registry | |||||||||
| California | 5840 | 41.4 | 49705 | 40.7 | 39004 | 40.3 | 15141 | 39.8 | <0.001 |
| Connecticut | 643 | 4.6 | 6368 | 5.2 | 4659 | 4.8 | 2064 | 5.4 | |
| Detroit | 651 | 4.6 | 6346 | 5.2 | 4939 | 5.1 | 2094 | 5.5 | |
| Georgia | 1830 | 13.0 | 13933 | 11.4 | 10855 | 11.2 | 3765 | 9.9 | |
| Iowa | 458 | 3.2 | 4212 | 3.4 | 3752 | 3.9 | 1850 | 4.9 | |
| Kentucky | 668 | 4.7 | 6345 | 5.2 | 5534 | 5.7 | 2006 | 5.3 | |
| Louisiana | 717 | 5.1 | 6199 | 5.1 | 5295 | 5.5 | 2051 | 5.4 | |
| New Jersey | 1518 | 10.8 | 13921 | 11.4 | 10057 | 10.4 | 4346 | 11.4 | |
| New Mexico | 238 | 1.7 | 2265 | 1.9 | 2180 | 2.3 | 842 | 2.2 | |
| Others (Hawaii, Alaska) | 272 | 1.9 | 2426 | 2.0 | 1905 | 2.0 | 706 | 1.9 | |
| Seattle | 843 | 6.0 | 7665 | 6.3 | 6363 | 6.6 | 2213 | 5.8 | |
| Utah | 431 | 3.1 | 2803 | 2.3 | 2294 | 2.4 | 961 | 2.5 | |
| Stage | |||||||||
| I | 3701 | 26.2 | 56408 | 46.2 | 54925 | 56.7 | 19902 | 52.3 | <0.001 |
| II | 7384 | 52.3 | 49022 | 40.1 | 32492 | 33.6 | 13880 | 36.5 | |
| III | 3024 | 21.4 | 16758 | 13.7 | 9420 | 9.7 | 4257 | 11.2 | |
| Histologic grade | |||||||||
| High, G3 | 7743 | 54.9 | 42543 | 34.8 | 24718 | 25.5 | 9228 | 24.3 | <0.001 |
| Low,intermediate (G1, G2) | 5757 | 40.8 | 75099 | 61.5 | 68884 | 71.1 | 27305 | 71.8 | |
| Other (G4)/unknown | 609 | 4.3 | 4546 | 3.7 | 3235 | 3.3 | 1506 | 4.0 | |
| ER status | |||||||||
| Positive∗ | 4049 | 28.7 | 99373 | 81.3 | 83281 | 86.0 | 33071 | 86.9 | <0.001 |
| Negative | 10060 | 71.3 | 22815 | 18.7 | 13556 | 14.0 | 4968 | 13.1 | |
| PR status | |||||||||
| positive∗ | 5315 | 37.7 | 88155 | 72.1 | 72651 | 75.0 | 28689 | 75.4 | <0.001 |
| negative | 8794 | 62.3 | 34033 | 27.9 | 24186 | 25.0 | 9350 | 24.6 | |
| HER2 status | |||||||||
| positive | 3540 | 25.1 | 21072 | 17.2 | 11580 | 12.0 | 3852 | 10.1 | <0.001 |
| borderlinea | 269 | 1.9 | 2594 | 2.1 | 2069 | 2.1 | 956 | 2.5 | |
| negative | 10300 | 73.0 | 98522 | 80.6 | 83188 | 85.9 | 33231 | 87.4 | |
| Molecular subtype | |||||||||
| HR+, lower grade (HR+, HER2- and G1/2) | 4483 | 31.8 | 65949 | 54.0 | 62554 | 64.6 | 25267 | 66.4 | <0.001 |
| HR+, high grade/HR + HER2+ | 5724 | 40.6 | 33323 | 27.3 | 20195 | 20.9 | 7488 | 19.7 | |
| HER2 (HR- and HER2+) | 976 | 6.9 | 6427 | 5.3 | 3437 | 3.5 | 1134 | 3.0 | |
| TN (HR- and HER2-) | 2757 | 19.5 | 14599 | 11.9 | 9105 | 9.4 | 3432 | 9.0 | |
| Unknown | 169 | 1.2 | 1890 | 1.5 | 1546 | 1.6 | 718 | 1.9 | |
| Chemotherapy | |||||||||
| Yes | 11252 | 79.8 | 65411 | 53.5 | 31884 | 32.9 | 3717 | 9.8 | <0.001 |
| No | 2857 | 20.2 | 56777 | 46.5 | 64953 | 67.1 | 34322 | 90.2 | |
| Radiotherapy | |||||||||
| Yes | 6553 | 46.4 | 65333 | 53.5 | 55515 | 57.3 | 14036 | 36.9 | <0.001 |
| No | 7556 | 53.6 | 56855 | 46.5 | 41322 | 42.7 | 24003 | 63.1 | |
| Surgery | |||||||||
| Yes | 13326 | 94.5 | 117738 | 96.4 | 93804 | 96.9 | 34689 | 91.2 | <0.001 |
| No | 783 | 5.5 | 4450 | 3.6 | 3033 | 3.1 | 3350 | 8.8 | |
Abbreviation: HER2, human epidermal growth factor receptor 2.
HR+, low grade: ER positive and/or PR positive, HER2 negative/low grade HR+, high grade/HR+, HER2+: ER positive and/or PR positive, HER2 negative/high grade, or ER positive and/or PR positive, HER2 positive.
HER2: ER negative, PR negative, and HER2 positive.
∗TN(Triple negative): ER negative, PR negative, and HER2 negative.
∗Borderline was included as positive.
a
The result of IHC, FISH, SISH etc.